Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check63 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check78 days agoChange DetectedThe webpage has been updated to include new information about a clinical trial for Recurrent Plasma Cell Myeloma, including the addition of a new registry identifier and collaborators, while significant details about the trial's objectives and treatment regimen have been removed.SummaryDifference42%
- Check85 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 25, 2025.SummaryDifference0.3%
Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.